Trastuzumab-emtansine versus other anti-HER2 regimens in early or unresectable or metastatic HER-2 positive breast cancer: systematic review and network meta-analysis.
Agustín CiapponiAriel Esteban BardachCarla ColaciFederico Rodriguez CairoliFernando J ArgentoErnesto KorbenfeldSebastian Garcia MartiPublished in: Revista peruana de medicina experimental y salud publica (2024)
NMA allows a ranking based on the comparative efficacy and safety among the interventions available. Although superior to other schemes, T-DM1 showed a lower efficacy performance in PFS and overall response rate and a trend towards worse overall survival than T-DXd.